Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by De Pas, T.
Right arrow Articles by de Braud, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Pas, T.
Right arrow Articles by de Braud, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:161-166, 2002
© 2002 European Society for Medical Oncology

Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas

T. De Pas1,+, G. Curigliano1, G. Masci1, C. Catania1, A. Comandone2, C. Boni3, A. Tucci4, O. Pagani5, E. Marrocco1 and F. de Braud1 on behalf of the Italian Sarcoma Group

1Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan; 2Division of Medical Oncology, Hospital Gradenigo, Torino; 3Medical Oncology Service, Arcispedale S. Maria Nuova, Reggio Emilia; 4Medical Oncology, Hospital Cardarelli, Napoli, Italy; 5Oncology Institute of Southern Switzerland, Bellinzona and Mendrisio, Switzerland

Received 14 March 2001; revised 3 August 2001; accepted 17 August 2001.

Purpose

To determine whether a prolonged 12-day continuous infusion allows the administration of high-dose ifosfamide (IFO) with an acceptable toxicity profile when combined with full-dose doxorubicin (Adriamycin®; ADM) as first-line chemotherapy in patients with advanced soft tissue sarcomas.

Patients and methods

Escalating doses of continuous infusion IFO (8–15 g/m2) given on days 1 to 12 in combination with ADM 75 mg/m2 given on day 8 and prophylactic granulocyte colony-stimulating factor support were administered every 4 weeks to 35 chemonaïve patients with advanced soft tissue sarcomas.

Results

The maximum tolerated dose was IFO 15 g/m2. Hematological toxicity was the main dose-limiting toxicity and was dose dependent. Furthermore, thrombocytopenia was cumulative. Grade 4 (WHO) neutropenia and thrombocytopenia were recorded in 48% and 14% of courses, respectively. Eight patients experienced febrile neutropenia. A partial response was observed in 16 out of 30 assessable patients [53%, 95% confidence interval (CI) 25–63]; median time to progression was 25 weeks (range 4–91).

Conclusions

This study proved that a prolonged 12-day continuous infusion allows an increase in the total IFO dose that can be safely combined with ADM. A multicentric phase II study by the Italian Sarcoma Group to assess its antitumor activity is currently ongoing in patients with advanced soft tissue sarcomas.

Key words: chemotherapy, continuous infusion, high dose, ifosfamide, soft tissue sarcomas


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
S. A. Welch and M. J. Moore
Combination Chemotherapy in Advanced Pancreatic Cancer: Time to Raise the White Flag?
J. Clin. Oncol., June 1, 2007; 25(16): 2159 - 2161.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. N. Gardner and M. Fernandes
New tools for cancer chemotherapy: computational assistance for tailoring treatments
Mol. Cancer Ther., October 1, 2003; 2(10): 1079 - 1084.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
H. Morioka, L. Weissbach, T. Vogel, G. P. Nielsen, G. T. Faircloth, L. Shao, and F. J. Hornicek
Antiangiogenesis Treatment Combined with Chemotherapy Produces Chondrosarcoma Necrosis
Clin. Cancer Res., March 1, 2003; 9(3): 1211 - 1217.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.